Literature DB >> 21234317

Reclassification of ICD-9 Codes into Meaningful Categories for Oncology Survivorship Research.

S R Rassekh1, M Lorenzi, L Lee, S Devji, M McBride, K Goddard.   

Abstract

Background. The International Classification of Disease, ninth revision (ICD-9) is designed to code disease into categories which are placed into administrative databases. These databases have been used for epidemiological studies. However, the categories used in the ICD9-codes are not always the most effective for evaluating specific diseases or their outcomes, such as the outcomes of cancer treatment. Therefore a re-classification of the ICD-9 codes into new categories specific to cancer outcomes is needed. Methods. An expert panel comprised of two physicians created broad categories that would be most useful to researchers investigating outcomes and morbidities associated with the treatment of cancer. A Senior Data Coordinator with expertise in ICD-9 coding, then joined this panel and each code was re-classified into the new categories. Results. Consensus was achieved for the categories to go from the 17 categories in ICD-9 to 39 categories. The ICD-9 Codes were placed into new categories, and subcategories were also created for more specific outcomes. The results of this re-classification is available in tabular form. Conclusions. ICD-9 codes were re-classified by group consensus into categories that are designed for oncology survivorship research. The novel re-classification system can be used by those involved in cancer survivorship research.

Entities:  

Year:  2010        PMID: 21234317      PMCID: PMC3018640          DOI: 10.1155/2010/569517

Source DB:  PubMed          Journal:  J Cancer Epidemiol        ISSN: 1687-8558


1. Background

The importance of a classification system for the grouping of causes of morbidity or mortality has long been known to be crucial for the study of disease. The first attempt to classify disease systematically has been attributed to Francois Bossier de Lacroix, (1706–1777), better known as Sauvages [1] in his treatise Nosologia Methodica, written in the 18th century. Subsequently, many groups have made attempts to create their own classification systems to compile quantitative data about various diseases within different population groups. In these systems, individual code categories are assigned to conditions that occur frequently and are associated with significant morbidity; others are grouped together, often by anatomical site or physiologic system [2]. Since the early 1900's, international collaborations have attempted to revise and update these classification systems and this has led to the development of the International Classification of Diseases, which is now under the direction of the World Health Organization. The first version of the International Classification of Diseases was adopted in 1900. The ninth version, known as ICD-9, was published in 1975 and uses a five-digit coding system where the categories are meaningful at the 3-digit level [3]. The ICD-9 has become a useful tool for health researchers, as the use of administrative databases in the study of diseases has flourished over the last decade. Administrative databases provide a quick and efficient method of eliciting clinical information regarding hospitalization, as compared to the historically used gold standard of chart review. These administrative databases were not intended for research but rather to collect information regarding resource utilization. However, studies have shown that clinical data extracted from hospital databases in Canada provide reliable data when compared to manual chart review [4]. There are limitations to these databases; it has been suggested that comorbidities in these databases may be underreported for certain codes [5]. A reorganization of ICD-9 codes has been completed for four major chronic conditions (coronary artery disease, congestive heart failure, asthma, and chronic obstructive pulmonary disease) by a group of researchers for the purpose of creating a consistent research tool for the study of these health problems [6]. These researchers used the consensus of experts in the field and followed the recommendations made by Fink et al. [7]. Their recommendations stated that a group consensus should focus on a carefully defined problem that could be investigated in a timely and economical way, that consensus panel members should be representative of their profession, and that decisions on important issues should be justified by available empirically derived data as well as by judgments and experience. The Childhood/Adolescent/Young Adult Cancer Survivor Program (CAYACS) is a research program investigating late outcomes in survivors of pediatric and young adult cancer through the linkage of administrative databases. One of the major aims of this program was to analyze hospitalizations in survivors of childhood and adolescent cancer occurring 5 years after the date of diagnosis. ICD-9 codes reported on the hospital separation forms of 5-year cancer survivors can be linked and compared with controls who did not have childhood cancer. In reviewing the ICD-9 coding book, it became clear that the categories used in this book were not ideally suited for research into cancer survivorship. Therefore, a reclassification of ICD-9 coding was needed that was specific for all cancer survivorship issues. The purpose of this paper is to develop this reclassification of the ICD-9 codes that can be used by all researchers in cancer survivorship. Specifically, this reclassification system can be used by researchers interested in iatrogenic late effects due to therapies given to patients with cancer. It can also be used to study the association of cancer with other diseases that may share etiologic determinants. Finally, it can also be used in Health Services research investigating the rates of hospitalizations or medical services use in those who had previously treated cancer.

2. Methods

The first step was to review the categories used in the ICD-9 and then to decide what categories would be useful for oncology outcome research. Two investigators (SRR and KG) decided which major categories should be included. These categories included both main categories and a few subcategories as required. It was decided to use a category called “other” to group together all codes which were not easily identifiable or did not seem as important for oncology research. The second step was then to create an expert panel which included a radiation oncologist, a pediatric oncologist, and a data coordinator with extensive knowledge in ICD-9 coding (KG, SRR, LL). All 3 members of the panel had experience in survivorship research and were involved in a study using administrative databases to look at long-term outcomes in children treated for cancer (the CAYACS program). This panel then systematically reviewed each code in the ICD-9 coding book and placed each code into its new category in an Excel database. The final step was the transformation of this spreadsheet (performed by ML) into a program that reads ICD-9 codes from a data file and assigns the correct category using R code (reference), so that this new database could be easily used in future studies.

3. Results

The categories decided upon by the panel are shown in Table 1. This changed the number of major categories from the 17 found in ICD-9 to 39 categories. The categories first used the ICD-9 categories served as a backbone and then new categories were created to encompass groups of conditions that would be of interest to those involved in survivorship research. After long discussion, the 2 clinicians involved in the study determined that these were the categories of choice.
Table 1

Categories created by the panel.

Infectious disordersInfertility disorders
NeoplasmsPerinatal conditions
Endocrine disordersSkin and subcutaneous disorders
Nutritional disordersMusculoskeletal and connective tissue disorders
Fluid and electrolyte disordersCongenital anomalies
Inherited metabolic, and immune disordersNonspecific abnormal findings
Hematologic disordersOther and unspecified mortality and morbidity
Psychiatric disordersInjuries
Substance abusePoisonings by drugs, medicaments, and biological
Neurological disorderssubstances
ENT and eye disordersEffects of foreign body entering through orifice
Cardiovascular disordersToxic effects of substances
Varicose veins, haemorrhoids, and lymphaticOther and unspecified effects of external causes
DisordersCertain adverse effects not elsewhere classified
Respiratory disordersComplications from a Procedure or Device
Dental disordersComplications of Medical Care
Digestive system disordersLate Effects
Genitourinary disordersExternal Causes (E Codes)
Gynecological disordersFactors Influencing Health Status and Contact with
Breast disordersHealth Services (V Codes)
Pregnancy, childbirth, and puerperiumMorphology of Neoplasms (M Codes)
The reclassification of the ICD-9 codes into the new categories is shown in Table 2. All the codes from the ICD-9 book were able to be incorporated into the new classification groups. The group was able to achieve full consensus for all codes. The majority of codes were easy to place into the new categories, but there were many codes that did not fit easily into a specific category. However, group consensus was achieved for all the reclassification choices.
Table 2

Full categorization of ICD-9 codes.

Infectious Disorders001–136, 320–326, 370.1, 370.3–370.5, 372.0-372.1, 373.4–373.6, 377.3, 380.1, 382, 383.0–383.2, 420–422, 447.7, 460-466, 480-487, 511.1, 513, 540.1, 567.0-567.2, 573.1-573.2, 577.0-577.1, 581.8, 583.8, 590, 595.4–595.8, 597, 598.0, 601.2, 601.4, 603.1, 604, 614.2–614.4, 616.0-616.1, 616.3-616.5, 681–686, 711, 727.0, 727.3, 728.0, 730, 785.4, 790.7-790.8

Central Nervous System Infections013, 036.0-036.1, 046–049, 053.0-053.1, 054.3, 054.7, 055.0, 056.0, 062–064, 072.1-072.2, 320–326, 331.5-331.6

Bacteremia Infections036.2, 038, 790.7

Endocarditis and Pericarditis Infections036.4, 420, 421

Hepatitis Infections070, 573.1-573.2

Gastrointestinal Infections007–009, 014, 054.2, 072.3, 120.1, 127, 129, 540.1, 567.0–567.2, 577.0-577.1

Genitourinary Infections016, 054.1, 072.0, 078.6, 110.3, 112.1-112.2, 131, 581.8, 583.8, 590, 595.4–595.8, 597, 598.0, 601.2, 601.4, 603.1, 604, 614.2–614.4, 616.0-616.1, 616.3–616.5

Sexually Transmitted Infections090–099, 447.7

Other Infections001–006, 010–012, 015, 017-018, 020–027, 030–035, 037, 039–041, 045, 050–052, 053.2–053.9, 054.0, 054.4–054.9, 055, 056.7–056.9, 057, 060-061, 065-066, 071, 072.7–072.9, 073–077, 078.0–078.5, 078.7-078.8, 079–088, 100–104, 110.0–110.2, 110.4–110.9, 111, 112.0, 112.3–112.9, 114–118, 120.0, 120.2–120.9, 121–126, 128, 130, 132–136, 370.1, 370.3–370.5, 372.0-372.1, 373.4–373.6, 377.3, 380.1, 382, 383.0–383.2, 422, 460–466, 480-487, 511.1, 513, 681–686, 711, 727.0, 727.3, 728.0, 730, 785.4, 790.8

Neoplasms140–239

Malignant Neoplasm of Breast174-175

Malignant Neoplasm of CNS191-192

Malignant Neoplasm of Thyroid Gland193

Leukemia204–208

Malignant Cancers of soft tissue, connective tissue and bone170-171

Malignant Cancers of Skin172-173

Endometrial Cancer182

Other Malignant Neoplasms140–169, 176–181, 183–190, 194–208

Benign Neoplasms210–224, 225.0-225.1, 225.8-225.9, 226–229

Meningiomas225.2–225.4

Carcinoma In Situ Tumours230–234

Neoplasm of Uncertain Behavior235–238

Neoplasm of Unspecified Nature239

Endocrine Disorders240–259

Thyroid Gland Disorders240–246

Diabetes Mellitus250

Hypothalamus/Pituitary Disorders253

Adrenal Gland Disorders255

Ovarian/Testicular Dysfunction Disorders256-257

Other Endocrine Disorders251-252, 254, 258-259

Nutritional Disorders260–275, 278, 783

Malnutritional/Anorexic Disorders260–263, 783.0, 783.2

Obesity Disorders278.0-278.1, 783.1

Vitamin Deficiency Disorders264–269
Other Nutritional Disorders270–275, 278.2–278.8, 783.3–783.9

Fluid And Electrolyte Disorders276

Inherited Metabolic and Immune Disorders277, 279

Hematologic Disorders280, 281, 282–289, 325, 415.1, 444, 451–453, 790.0

Anaemias280, 281, 282–285

Coagulation Defects286-287, 325, 415.1, 444, 451–453

White Blood Cell Defects288

Other Hematologic Disorders289, 790.0

Psychiatric Disorders293-298, 300-302, 306-309, 311-313, 314, 316

Depression Disorders300.4, 309.0-309.1, 311, 313.1

Psychosis Disorders293–298

Anxiety Disorders300.0–300.3, 300.5–300.9, 308, 309.2, 313.0

Personality Disorders301, 312

Eating Disorders307.1–307.5

Hyperkinetic Syndrome (Attention Deficit Hyperactivity Disorders)314

Other Psychiatric Disorders302, 306, 307.0, 307.2–307.4, 307.6–307.9, 309.3–309.9, 313.2–313.9, 316

Substance Abuse291-292, 303–305

Alcohol Abuse291, 303

Drug Abuse292, 304-305

Neurological Disorders290, 299, 310, 315, 317–319, 327, 330, 331.0–331.5, 331.7–331.9, 332–337, 340-359, 430–437, 780-781, 784.0, 797

Cognitive Disorders290, 299, 310, 315, 317–319, 797

Cerebral Degeneration Disorders330, 331.0-331.2, 331.7–331.9

Hydrocephalus Disorders331.3–331.5

Seizure Disorders345, 780.3

Coma780

Migraine and Headaches346

Cerebrovascular Disorders430–437

Spinal Cord Disorders336, 344

Other Neurological Disorders327, 784

Ent and Eye Disorders360–369, 370.0, 370.2, 370.6–370.9, 371, 372.3–372.9, 373.0–373.3, 373.8-373.9, 374–376, 377.0–377.2, 377.4–377.9, 378-379, 380.0, 380.2–380.9, 381, 383.3–383.9, 384–389, 470–478, 526–529, 784.1–784.9

Eye and Adnexa Disorders360–369, 370.0, 370.2, 370.6–370.9, 371, 372.3–372.9, 373.0–373.3, 373.8-373.9, 374–376, 377.0–377.2, 377.4–377.9, 378-379

Ear Disorders380.0, 380.2–380.9, 381, 383.3–383.9, 384–387

Hearing Loss Disorders388-389

Nasal and Oral Disorders470–478, 526–529, 784.1–784.9

Cardiovascular Disorders390–398, 401–414, 416-417, 423–429, 440–443, 446–448, 458-459, 785.0–785.3, 785.5, 785.9, 794.3

Cardiomyopathy and Heart Failure Disorders425, 428

Arryhthmia Disorders426-427, 785.0-785.1, 794.3
Hypertensive Disorders401–405

Atherosclerotic Disorders440

Ischaemic Heart Disorders410–414

Hypotensive Disorders458, 785.5

Other Cardiovascular Disorders390–398, 416-417, 423-424, 429, 441–443, 446–448, 459, 785.2-785.3, 785.9

Varicose Veins, Haemorrhoids, and Lymphatic Disorders454–457, 785.6

Varicose Veins and Hemorrhoids Disorders454–456

Lymphatic Disorders457, 785.6

Respiratory Disorders415.0, 490–496, 500–508, 510–512, 514–519

Radiation Manifestations508.0-508.1

Dental Disorders520–525

Digestive System Disorders530–537, 540.0, 540.9, 541–543, 550–553, 555–558, 560, 562, 564–566, 567.8–567.9, 568–572, 573.0, 573.3–573.9, 574–576, 577.2–577.9, 578-579, 787, 789

Irritable Bowel Disorders555-556, 558

Liver Disorders570–572, 573.0, 573.3–573.9

Biliary Tract and Gallbladder Disorders574–576

Stomatitis528

Esophagitis530

Other Digestive System Disorders530–537, 540.0, 540.9, 541–543, 550–553, 557, 560, 562, 564–566, 567.8-567.9, 568-569, 577.2–577.9, 578-579, 787, 789

Genitourinary Disorders580, 581.0–581.3, 581.9, 582, 583.0–583.7, 583.9, 584–589, 591–594, 595.0–595.3, 595.9, 596, 598.1–598.9, 599-600, 601.0-601.1, 601.3, 601.8-601.9, 602, 603.0, 603.8-603.9, 605, 607-608, 788

Renal Disorders580, 581.0–581.3, 581.9, 582, 583.0–583.7, 583.9, 584–589, 591

Calculus Disorders592, 594

Bladder Disorders595.0–595.3, 595.9, 596

Urethral Disorders598.1–598.9, 599

Other Genitourinary Disorders600, 601.0-601.1, 601.3, 601.8-601.9, 602, 603.0, 603.8-603.9, 605, 607-608, 788

Gynecological Disorders614.0-614.1, 614.5–614.9, 615, 616.2, 616.8-616.9, 617–627, 629

Menstrual Disorders626

Menopausal Disorders627

Other Gynecological Disorders614.0-614.1, 614.5–614.9, 615, 616.2, 616.8-616.9, 617–625, 629

Breast Disorders611

Pregnancy, Childbirth, and Puerperium630–648, 650–676, V22–V24, V27

Spontaneous Abortions630–632, 634

Therapeutic Abortions635–638

Ectopic Pregnancy633

Complications Following Abortion, Ectopic, and Molar Pregnancies639

Complications Related to Pregnancy640–648

Indication for Care in Pregnancy, Labour and Delivery650–659

Complications Occurring in Labour and Delivery660–669

Complications of the Puerperium670–676

Supervision and Pregnancy StateV22–V24

Delivery OutcomeV27
Infertility Disorders606, 628, 792.2

Male Infertility606, 792.2

Female Infertility628

Perinatal Conditions760–779, V30–V39

Perinatal Conditions760–799

Birth OutcomeV30–V39

Skin and Subcutaneous Disorders680, 690–698, 700–709, 782

Hair and Hair Follicles Disorders704

Other Skin and Subcutaneous Disorders680, 690–698, 700–703, 705–709, 782

Musculoskeletal and Connective Tissue Disorders710, 712–726, 727.1–727.2, 727.4–727.9, 728.1-728.2, 729, 731–739

Rheumatological Disorders710, 712–716, 725-726

Joint Disorders717–719

Spine Disorders720–724, 737

Other Musculoskeletal and Connective Tissue Disorders727.1-727.2, 727.4–727.9, 728.1–728.8, 729, 731–736, 738-739

Congenital Anomalies740–759

Nonspecific Abnormal Findings790.1–790.6, 790.9, 790.9, 791, 792.0-792.1, 792.3–792.9, 793, 794.0–794.2, 794.4–794.9, 795-796

Other and Unspecified Morbidity and Mortality798-799

Injuries800–848, 850–854, 860–887, 890–897, 900–904, 910–929, 940–959

Fractures (Excluding Skull and Spinal Fractures)807–829

Head Injuries (Including Skull Fractures)800–804, 850–854, 870–873, 900, 910, 918, 920-921, 925, 950-951

Spinal Injuries (Including Spinal Fractures)805-806, 839–839.5, 846-847, 952–954

Burns940–949

Other Injuries (Excluding Fractures)830–838, 839.6–839.9, 840–845, 848, 860–869, 874–887, 890–897, 901–904, 911–917, 919, 922–924, 926–929, 955–959

Poisonings by Drugs, Medicaments, and Biological Substances960–979

Effects of Foreign Body Entering Through Orifice930–939

Toxic Effects of Substances980–989

Other and Unspecified Effects of External Causes990–994

Certain Adverse Effects Not Elsewhere Classified995

Adverse Effects Due to Drug, Medicament, or Biological Substance995.0, 995.2, 995.4

Other Adverse Effects995.1, 995.3, 995.5, 995.8

Complications from a Procedure or Device996–998

Complications of Medical Care999

Late Effects137–139, 268.1, 326, 438, 905-909, E929, E959, E969, E977, E989, E999

Late Effects of Infectious and Parasitic Diseases137–139

Late Effects of Ricketts268.1

Late Effects of Intracranial Abscess or Pyogenic Infection326

Late Effects of Cerebrovascular Disease438

Late Effect of Poisoning Due to Drug, Medicament, or Biological Substance909.0

Late Effect of Toxic Effects of Nonmedical Substances909.1

Late Effects of Radiation909.2

Late Effects of Complications of Surgical and Medical Care909.3

Late Effects of Other and Unspecified Causes909.4–909.9

Late Effects of Injuries905–908
Late Effects of Accidental InjuryE929

Late Effects of Self-Inflicted InjuryE959

Late Effects of Injury Purposely Inflicted by Other PersonE969

Late Effects of Injuries Due to Legal InterventionE977

Late Effects of Injury, Undetermined Whether Accidentally or Purposely InflictedE989

Late Effects of Injury Due to War OperationsE999

External Causes (E Code) (Supplementary Codes)

External Causes of InjuryE800–E807, E810–E838, E840–E848, E880–E888, E890–E928, E970–E976, E978, E980–E988, E990–E998

Railway AccidentsE800–E807

Motor Vehicle Accidents-Traffic and NontrafficE810–E825

Pedal Cycle AccidentsE826

Other Transport AccidentsE827–E838, E840–E848

All Accidental FallsE880–E888

All Accidents Caused by Fire and FlamesE890–E899

All Other AccidentsE900–E928

All Injuries Caused by Legal InterventionE970–E976, E978

Injury Undetermined Whether Accidentally or Purposely InflictedE980–E988

Injury Resulting From Operations of WarE990–E998

External Causes Of Poisoning By Drugs, Medicaments, And BiologicalsE850–E858

External Causes Of Poisoning By Solid And Liquids, Gases And VapoursE860–E869

Accidental Poisoning by Alcohol, Not Elsewhere ClassifiedE860

Other Accidental PoisoningsE861–E869

Misadventures To Patients During Surgical And Medical CareE870–E876

Abnormal Reaction Or Complication To Patient After Surgical Or Medical CareE878-E879

Adverse Effects In Therapeutic Use Of Drugs, Medicaments, And BiologicalsE930–E949

Chemotherapy Adverse EffectsE930.7–E933.1

Other Adverse EffectsE930.0–E930.6, E930.8-E930.9, E931-E932, E933.0, E933.2–E933.9, E934–E949

Suicides And Self-Inflicted InjuryE950–E958

Homicide And Injury Purposely Inflicted By Other PersonsE960–E968

Factors Influencing Health Status And Contact With Health Services (V Code)V01–V21, V25-V26, V28, V40–V82

Personal History of Malignant NeoplasmV10

Family History of Malignant NeoplasmV16

Personal History of Mental DisorderV11

Mental and Behavioral ProblemsV40

Health Supervision of Infant or ChildV20

Constitutional States In DevelopmentV21

Problems With SightV41.0-V41.1

Problems With HearingV41.2-V41.3

Elective Surgery for Purposes Other Than Remedying Health StatesV50, V51

Fitting and Adjustment of Hearing AidV53.2

Fitting and Adjustment of Cardiac PacemakerV53.3

Radiotherapy SessionV58.0
Maintenance ChemotherapyV58.1

Housing, Household, and Economic CircumstancesV60.0-V60.2

Other Family CircumstancesV61

UnemploymentV62.0

Observation For Suspected Malignant NeoplasmV71.1

Special Screening For Malignant NeoplasmsV76

Other Factors Influencing Health Status and Contact With Health ServicesV01–V09, V12–V15, V17–V19, V25-V26, V28, V41.4–V41.9, V42–V49, V52, V53.0-V53.1, V53.4–V53.9, V54–V57, V58.2–V58.9, V59, V60.3–V60.9, V62.1–V62.9, V63–V70, V71.0, V71.2–V71.9, V72–V75, V77–V82

Morphology Of Neoplasms (M Codes)M8000-M9970

4. Discussion

The development of the ICD-9 codes has enabled health administrators and policy makers to investigate the frequency and causes for hospitalizations across jurisdictions. This coding system categorizes headings into 17 major groupings. There has been recent interest in the use of these hospital administrative databases to help answer epidemiological hypotheses. However, as the coding system is generalized to the entire spectrum of health conditions, it is not ideal for specific groups of interest. This became evident to our CAYACS program when we were attempting to use ICD-9 codes to analyze causes of hospitalizations in cancer survivors. The existing numerical groupings were not ideal for survivorship research. For instance, causes of infections were scattered throughout the ICD-9 coding groupings despite having infection as a major grouping. The hospital's data coordinator could code an infection based on the pathogen (codes 001-139.8) or could code based on the system affected by the infection (codes scattered throughout the range). For a clinical researcher who is interested in all infections in a group of individuals with a specific health condition, the ICD-9 code groupings are not suited for this type of research. This becomes even more important when considering a very specific area of research, such as the treatment of cancer and its late outcomes. The purpose of this study was to reclassify the ICD-9 codes into practical groupings that can be used by a health researcher specifically for cancer follow-up outcomes. This study has therefore reclassified the ICD-9 codes into categories which are useful to those involved in oncology research using administrative databases. This reclassification system can be used by all groups looking at causes of hospitalization in those diagnosed with cancer, whether these patients are on active treatment or are in posttherapy surveillance as long-term survivors. All the codes in ICD-9 are accounted for and have been placed into specific categories. Subcategories were created that would help distinguish areas of interest within larger groups. For instance, within the cardiovascular system it is important to distinguish hypertension, myocardial infarction, arrhythmias, valvular disease and cardiomyopathy from each other, as each subcategory would likely have differing attributable factors and risks. By separating out these different conditions, we can study the the long-term risk of hospitalization associated with different initial childhood cancer diagnoses and therapies. We can for example, measure the risk of hospitalization for different cardiac conditions in long-term survivors treated for childhood Hodgkin lymphoma treated with mantle radiotherapy. A strength of this study is that consensus was easily achieved for all ICD-9 codes between the 3 members of the panel. The inclusion of a senior data coordinator who has extensive experience and expertise in coding in hospital discharges gave insight into the practicality of coding. As all 3 members of the panel are involved in survivorship research, the new classification scheme was based on experience with data derived from ICD9-coding. The main limitation of this study is that it represents the opinion of only one group of clinicians. Certainly others may have a few subtle changes they would suggest to the classifications or the categories in general.

5. Conclusions

By our accounts this is the first reclassification of the ICD-9 codes into new diagnostic groupings that are more useful for the clinical researcher. Moreover, this new classification system is ideal for oncology-specific outcomes and can therefore be used by all researchers in the study of cancer treatment and survivorship.

Conflict of Interests

The authors declare that they have no conflict or-interests.

Authors Contributions

S. R. Rassekh conceived the study, participated in the design, was on the expert panel that performed the reclassification, and drafted the manuscript. M. Lorenzi helped design the study, created all the tables, and helped draft the manuscript. L. Lee helped design the study and was on the expert panel that performed the reclassification and helped draft the manuscript. S. Devji helped in the design of the study and in drafting the manuscript. M. McBride helped design the study, is the primary investigator of the CAYACS project which helped fund this study, and helped draft the manuscript. K. Goddard helped to conceive the study, participated in the design, was on the expert panel that performed the reclassification, and helped draft the manuscript. All authors read and approved the final manuscript.
  3 in total

1.  Co-morbidity data in outcomes research: are clinical data derived from administrative databases a reliable alternative to chart review?

Authors:  K H Humphries; J M Rankin; R G Carere; C E Buller; F M Kiely; J J Spinelli
Journal:  J Clin Epidemiol       Date:  2000-04       Impact factor: 6.437

2.  Consensus methods: characteristics and guidelines for use.

Authors:  A Fink; J Kosecoff; M Chassin; R H Brook
Journal:  Am J Public Health       Date:  1984-09       Impact factor: 9.308

3.  Coding algorithms for defining comorbidities in ICD-9-CM and ICD-10 administrative data.

Authors:  Hude Quan; Vijaya Sundararajan; Patricia Halfon; Andrew Fong; Bernard Burnand; Jean-Christophe Luthi; L Duncan Saunders; Cynthia A Beck; Thomas E Feasby; William A Ghali
Journal:  Med Care       Date:  2005-11       Impact factor: 2.983

  3 in total
  6 in total

1.  Modeling temporal relationships in large scale clinical associations.

Authors:  David A Hanauer; Naren Ramakrishnan
Journal:  J Am Med Inform Assoc       Date:  2012-09-27       Impact factor: 4.497

Review 2.  Using Phecodes for Research with the Electronic Health Record: From PheWAS to PheRS.

Authors:  Lisa Bastarache
Journal:  Annu Rev Biomed Data Sci       Date:  2021-07-20

3.  Allergic Reactions Captured by Voluntary Reporting.

Authors:  Kimberly G Blumenthal; Anna R Wolfson; Yu Li; Claire M Seguin; Neelam A Phadke; Aleena Banerji; Elizabeth Mort
Journal:  J Patient Saf       Date:  2021-12-01       Impact factor: 2.844

4.  Human-Disease Phenotype Map Derived from PheWAS across 38,682 Individuals.

Authors:  Anurag Verma; Lisa Bang; Jason E Miller; Yanfei Zhang; Ming Ta Michael Lee; Yu Zhang; Marta Byrska-Bishop; David J Carey; Marylyn D Ritchie; Sarah A Pendergrass; Dokyoon Kim
Journal:  Am J Hum Genet       Date:  2018-12-29       Impact factor: 11.025

5.  Epidemiology of acute pancreatitis in hospitalized children in the United States from 2000-2009.

Authors:  Chaitanya Pant; Abhishek Deshpande; Mojtaba Olyaee; Michael P Anderson; Anas Bitar; Marilyn I Steele; Pat F Bass; Thomas J Sferra
Journal:  PLoS One       Date:  2014-05-07       Impact factor: 3.240

6.  Follicle-stimulating hormone (FSH) levels prior to prostatectomy are not related to long-term oncologic or cardiovascular outcomes for men with prostate cancer.

Authors:  Kassim Kourbanhoussen; France-Hélène Joncas; Christopher J D Wallis; Hélène Hovington; François Dagenais; Yves Fradet; Chantal Guillemette; Louis Lacombe; Paul Toren
Journal:  Asian J Androl       Date:  2022 Jan-Feb       Impact factor: 3.285

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.